BACKGROUND: Novel predictors of prognosis and treatment response for prostate cancer (PCa) are required to better individualize treatment. Single-nucleotide polymorphisms (SNPs) in four genes directly (XRCC5 (X-ray repair complementing defective repair in Chinese hamster cells 5) and XRCC6 (X-ray repair complementing defective repair in Chinese hamster cells 6)) or indirectly (PARP1 and major vault protein (MVP)) involved in non-homologous end joining were examined in 494 Spanish PCa patients. METHODS: A total of 22 SNPs were genotyped in a Biotrove OpenArray NT Cycler. Clinical tumor stage, diagnostic PSA serum levels and Gleason score at diagnosis were obtained for all participants. Genotypic and allelic frequencies were determined using the web-based environment SNPator. RESULTS: (XRCC6) rs2267437 appeared as a risk factor for developing more aggressive PCa tumors. Those patients carrying the GG genotype were at higher risk of developing bigger tumors (odds ratio (OR) = 2.04, 95% confidence interval (CI) 1.26-3.29, P = 0.004), present higher diagnostic PSA levels (OR = 2.12, 95% CI 1.19-3.78, P = 0.011), higher Gleason score (OR = 1.65, 95% CI 1.01-2.68, P = 0.044) and D'Amico higher risk tumors (OR = 2.38, 95% CI 1.24-4.58, P = 0.009) than those patients carrying the CC/CG genotypes. Those patients carrying the (MVP) rs3815824 TT genotype were at higher risk of presenting higher diagnostic PSA levels (OR = 4.74, 95% CI 1.40-16.07, P = 0.013) than those patients carrying the CC genotype. When both SNPs were analyzed in combination, those patients carrying the risk genotypes were at higher risk of developing D'Amico higher risk tumors (OR = 3.33, 95% CI 1.56-7.17, P = 0.002). CONCLUSIONS: We believe that for the first time, genetic variants at XRCC6 and MVP genes are associated with risk of more aggressive disease, and would be taken into account when assessing the malignancy of PCa.
INTRODUCTION
Prostate cancer (PCa) is a complex disease conditioned by hormonal and genetic factors. Tumor staging, tumor grading in terms of Gleason score and diagnostic PSA serum levels are used in the daily clinical practice to classify patients into different prognostic risk groups that condition treatment decisions. However, these clinical prognostic factors only explain a proportion of the patient-to-patient variation observed in the clinical outcome, 1 and it seems that better predictors of individualized prognosis and treatment response are urgently needed.
DNA double-strand break (DSB) is the most detrimental form of DNA damage, leading cells to chromosomal breakage and rearrangements. 2 DSBs can have exogenous (that is, exposure to ionizing radiation) and endogenous (that is, due to reactive oxygen species) origin, and can also be generated during somatic recombination, DNA replication and when DNA single-strand breaks are encountered. 2 Unrepaired or misrepaired DSBs would cause cell death, genomic instability and/or oncogenic transformation. 3 In eukaryotic cells, DSBs are repaired by two different pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). 4 Recently, single-nucleotide polymorphisms (SNPs)-defined as inherited mutations that are present in 41% of the population-in HR genes have been proposed as novel factors associated with PCa aggressiveness. 5 Because of the complexity of mammalian genomes, searching of homologous sequences for HR is not efficient. Thus, NHEJ has a predominant role in DSB repair. 6 This fact makes sense when is taken into account that most of the mammalian genome consists of non-coding sequences. 7 Thus, common variants in genes involved in DNA DSB repair are good candidates for low-penetrance cancer biomarkers. 8 The NHEJ repair mechanism starts with the recruitment of Ku70/ Ku80 proteins to the DNA ends. Ku70 is encoded by the X-ray repair complementing defective repair in Chinese hamster cells 6 (XRCC6) gene, whereas Ku80 is encoded by the X-ray repair complementing defective repair in Chinese hamster cells 5 (XRCC5) gene. Although other proteins are involved in end ligation (that is, DNA protein kinase (DNA-PK), XRCC4 or ligase IV (LIG4)), the well function of the Ku70/Ku80 complex is critical when NHEJ starts. 9 To our knowledge, studies concerning polymorphic variants of NHEJ genes have not been done in PCa.
Vaults are ribonucleoprotein particles with a hollow barrel-like structure. 10 It is composed of three proteins: the major vault protein (MVP), the vault poly(adenosine diphosphate-ribose) polymerase also known as VPARP, and telomerase-associated protein-1, together with small untranslated RNA (vRNA). Classically, MVP has been associated with the development of drug resistance. 11 However, in recent years there has been increasing interest in MVP, especially as MVP transcription and protein levels are increased in response to DNA-damaging agents including ionizing radiation. 12 In addition to its implication in the regulation of several cellular processes including transport mechanisms, signal transduction and immune responses, 13 the interaction with partners such as PTEN or BCL-2 suggests a role in the cell fate. 14, 15 Furthermore, MVP has been recently linked to DSB repair machinery due to an association with Ku70/Ku80 expression. 16 Thus, SNPs in MVP would have a role in PCa behavior, due to the role in the resistance to treatment, the regulation of apoptosis or the association with DNA damage repair mechanisms. 13 Poly[ADP-ribose] synthase 1 is a protein encoded by the gene PARP1, which is associated with differentiation, proliferation and tumor transformation.
17 PARP1 seems to have a role in DNA DSB repair through an interaction with BRCA1/2 and other genes. 18 Moreover, PARP1 and Ku compete for repair of DNA DSBs by different NHEJ pathways. 19 In the last years, PARP1 inhibitors have shown promising activity in ovarian and breast cancers patients with BRCA1/2 mutation, 20 and also in PCa patients. 21 The fact that PARP1 is a crossroad between HR and NHEJ and it is also of interest as a novel therapeutic target makes this gene a good candidate associated with tumor aggressiveness. Nowadays, the role of single-nucleotide variations in PARP1 has not been studied in the context of PCa.
The aim of this study was to test the hypothesis that genetic variants in genes involved directly (XRCC6 and XRCC5) or indirectly (MVP and PARP1) in DNA DSB repair confer increased risk of more aggressive PCa. To our knowledge, this is the first time that SNPs located in these genes are studied in PCa patients. Clinical tumor size (cT), diagnostic PSA serum levels and Gleason score 25 were recruited for all PCa patients. cT was assessed by digital rectal examination followed by transrectal ultrasonography and magnetic resonance imaging; PSA serum levels were assessed by chemiluminescence in an Architect i2000 analyzer (Abbott Laboratories, Lake Bluff, IL, USA); Gleason score was determined in the biopsy specimen by a specialized genitourinary pathologist from each institution. Subjects were categorized into three risk-based recurrence groups according to D'Amico classification: 26 low, intermediate and high risks. After collecting demographic and clinical data, a blood sample was taken after the signature of informed consent. All samples were sent by courier to the Hospital Universitario de Gran Canaria Dr Negrín for DNA isolation and genotype analyses.
MATERIALS AND METHODS Patients
DNA isolation and quantification DNA was isolated from 300 μl of whole-blood in an iPrep™ Purification Instrument using the iPrep™ PureLink™ gDNA Blood Kit (Invitrogen, by Life Technologies, Carlsbad, CA, USA), and its integrity was determined by NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA).
Selection criteria for SNPs
SNPs were selected using data of individuals with European ancestry (CEU) from the HapMap Project (available at: www.hapmap.org). Pairwise linkage disequilibrium tagging was achieved with the Haploview v4.2 software. 27 This strategy is based on the haplotype blocks formed by clustered SNPs. 28 By selecting a modest number of SNPs within a block, it is possible to recover up to 95% of the heterozygosity present at a locus. The R 2 given by Haploview was 40.95 for all genes.
Thus, a total of 22 SNPs in 4 different genes involved in DNA DSB repair were studied (Supplementary Table S1 ): XRCC6, rs5751131, rs2267437, rs11912946, rs7291732, rs881092; XRCC5, rs16855458, rs9288516, rs1051677, rs1051685; PARP1, rs8679, rs3219123, rs1805410, rs3219062, rs1805414, rs1805404, rs3219027; and MVP, rs9923649, rs12149514, rs4788186, rs3815824, rs35916172, rs3764944.
Genotyping
The SNP genotyping was performed in a Biotrove OpenArray NT Cycler (Applied Biosystems, Foster City, CA, USA). 29 DNA samples loaded in the OpenArray (OA) had a A260/A280 and A260/230 ratio of 1.7-1.9, and were adjusted to 50 ng μl − 1 . A total of 300 ng of genomic DNA was used. A final amount of 150 ng was incorporated into the array with the autoloader, and was genotyped according to the manufacturer's recommendations. A non-template control consisting of DNase-free double-distilled water was introduced within each assay. When the DNA and master mix were transferred, the loaded OA plate was filled with an immersion fluid and sealed with glue. The multiplex TaqMan assay reactions were carried out in a Dual Flat Block (384-well) GeneAmp PCR System 9700 (Applied Biosystems) with the following PCR cycle: an initial step at 93°C for 10 min followed by 50 cycles of 45 s at 95°C, 13 s at 94°C and 2:14 min at 53°C; followed by a final step during 2 min at 25°C and holding at 4°C.
The fluorescence was read using the OpenArray ® SNP Genotyping Analysis software version 1.0.5. (Applied Biosystems). The genotyping analysis was made with the TaqMan Genotyper software version 1.0.1 (available at: ttp://www.invitrogen.com) using autocalling as the call method. The quality value of the data points was determined by a threshold above 0.95. Genotype analysis was performed with the same batch of chips and by the same investigator, as previously reported. 5, 23, 24 About 10% of the samples were randomly selected for confirmation, and the results were all consistent.
Statistical analysis
Genotype and allelic frequencies were determined using the web-based environment SNPator (SNP Analysis To Results, from the Spain's National Genotyping Centre and the National Institute for Bioinformatics). 30 Relative excess of heterozygosity was determined to check compatibility of genotype frequencies with Hardy-Weinberg equilibrium. Thus, P-values from the standard exact Hardy-Weinberg equilibrium lack of fit test were calculated using SNPator. Comparisons of genotypic and allelic frequencies were also done in SNPator. All additional statistical analyses were performed using PASW Statistics 15 (IBM, Armonk, NY, USA) as follows: descriptive analyses were conducted for clinical variables, categorical variables were represented as absolute numbers and percentages, comparisons between groups were performed using chi-squared test (categorical variables), the associations between clinical variables and genetic variables were analyzed using a linear additive model employing logistic regressions. Different genetic models were taken into account.
RESULTS

Intra-ethnic variations of SNPs
All the genotyped samples met the quality criteria stated above. A total of 601 PCa patients were genotyped for 22 SNPs. Of the 13 222 possible determinations, 12 608 were successfully genotyped (95.0%).
We have previously shown that differences in the distribution of genotypes within different populations of the same ethnicity are an important confounding factor in genetics epidemiology. 23, 24 Thus, we first analyzed the genotype distribution among subjects from different Spanish regions, highlighting that all PCa patients were from the Caucasian origin. The genotypic and allelic frequencies are shown in Supplementary Table S2 . We observed that 9 of the 22 analyzed SNPs were differentially distributed: (XRCC6) rs5751131, rs2267437, rs7291732, rs881092; (XRCC5) rs1051677, (PARP1) rs3219123, rs1805410, rs1805414; and (MVP) rs4788186. As expected, Andalusian population showed a genotypic and allelic distribution clearly different from those reported among subjects from Basque Country, Canary Islands and Catalonia. Thus, we excluded Andalusian patients from subsequent analyses to homogenize the sample and minimize bias. We have previously followed this strategy of analysis. 5 Clinical variables associated with individual SNPs A total of 494 PCa were included in the subsequent association studies. Distribution of clinical variables is detailed in Table 1 . The majority of PCa patients were cT1a-cT2a (54.7%), PSA o10 ng ml − 1 (61.9%) and Gleason score o 7 (45.7%). Subsequently, a total of 120 patients (61.5%) were classified as lowintermediate risk tumors according to D'Amico classification.
Among the 22 analyzed SNPs, (XRCC6) rs2267437, (XRCC5) rs1051685, (PARP1) rs3219123 and (MVP) rs3815824, were significantly different distributed among PCa patients according to the clinical variables (Table 2) . Genotype distribution was consistent with Hardy-Weinberg equilibrium (data not shown).
We observed that rs2267437 was significantly associated with the cT (χ 2 test, P = 0.004). Thus, among the 249 PCa patients with cT1a-cT2a tumors, 37 carried the GG genotype (14.8%), while among the 183 PCa patients with cT2b-cT4 tumors, 48 carried the GG genotype (26.2%). Similar results were observed regarding to Gleason score and D'Amico risk groups (χ 2 test, P = 0.037 and P = 0.015, respectively) ( Table 2 ). In both cases, GG carriers showed more aggressive tumor characteristics; thus, GG genotype was detected in 12 out of 110 low-risk tumors and in 73 out of 323 intermediate-high risk tumors (10.9 vs 22.6%, respectively). Univariate analyses showed that GG genotype for (XRCC6) rs2267437 appeared as a risk factor for developing more aggressive PCa tumors ( Table 3 ). The fact that recessive and homozygote models showed significant results reinforces the role of GG genotype as a factor of worst tumor characteristics. In that sense, those PCa patients carrying the GG genotype were at higher risk of developing bigger tumors (odds ratio (OR) = 2.04, 95% confidence interval (CI) 1.26-3.29, P = 0.004), present higher diagnostic PSA levels (OR = 2.12, 95% CI 1.19-3.78, P = 0.011), higher Gleason score (OR = 1.65, 95% CI 1.01-2.68, P = 0.044) and D'Amico higher risk tumors (OR = 2.38, 95% CI 1.24-4.58, P = 0.009) than those patients carrying the CC/CG genotypes (Table 3) .
We observed that levels of diagnostic PSA were associated with three SNPs located in three different genes ( carried the (XRCC5) rs1051685 G allele (19.3%), while 8 out of 79 subjects with initial PSA levels ⩾ 20 ng ml − 1 carried the G allele (10.1%) (χ 2 test, P = 0.007). This result suggests that G allele appeared as a protective factor, a fact reinforced in univariate analysis: those PCa patients carrying the AG genotype were at lower risk of present higher diagnostic PSA levels (OR = 0.388, 95% CI 0.16-0.93, P = 0.033) than those patients carrying the AA genotype (Heterozygote model, data not shown). On the contrary, those PCa patients carrying the (MVP) rs3815824 TT genotype were at higher risk of presenting higher diagnostic PSA levels (OR = 4.74, 95% CI 1.40-16.07, P = 0.013) than those patients carrying the CC genotype (Homozygous model, data not shown). Finally, although (PARP1) rs3219123 was significantly associated with diagnostic PSA levels (χ 2 test, P = 0.041; Table 2 ), this SNP did not appear as a risk factor for that clinical variable in univariate analysis (data not shown).
Combined analyses of multiple SNPs
As it is plausible that the genes considered in the present study contribute to PCa behavior-due to a direct or indirect interaction with NHEJ pathway-we estimated the combined effect of the significantly associated genes (Figure 1 ). We considered (XRCC6) rs2267437 as the basics for these analyses, because its high impact in tumor characteristics (as previously shown in Tables 2 and 3) . Although the combination with (XRCC5) was not significant (OR = 2.11, 95% CI 0.91-4.94), the combined role of (XRCC6) rs2267437 with (PARP1) rs3219123 or (MVP) rs3815824 was risk factor associated with the D'Amico risk group. Thus, PCa patients carrying genotypes different from those considered as reference (CC+CC and CC+GG for rs2267437+rs3815824 and rs2267437 +rs3219123, respectively) were at higher risk of developing intermediate-high D'Amico risk groups (Figure 1) . Interestingly, the combination of these three SNPs did not showed a significant increment in the risk, suggesting that (XRCC6) rs2267437 and (MVP) rs3815824 have a predominant role in PCa tumor behavior (OR = 3.33, 95% CI 1.56-7.17, P = 0.002). 5 In the present study, we focused in the study of classical genes involved in NHEJ (XRCC6 and XRCC5) as well as other genes associated with DSB DNA repair (PARP1 and MVP). To our knowledge, this is the first comprehensive study that analyzes the possible role of these four genes and its influence in PCa behavior. Although it is a candidate gene study, we used an SNP tagging approach that reduces the bias inherit to the selection of well-published SNPs and allows the inclusion of novel genetic variants with possible new biological roles. A total of 601 PCa patients from 4 different Spanish regions were included in the study. Intra-ethnic variations of genotype and allelic frequencies are considered as an important confounding factor frequently obviated. Confounding would arise if the population contained several ethnic groups, if allele frequencies at the locus of interest differed between groups and if disease frequency also differed between groups for reasons quite unrelated to the locus of interest. 31 The phenomenon was previously observed in our series, 23, 24 a fact explained by differences in the natural history of the populations. 32, 33 As expected, the Andalusian population showed significant differences in genotype and allelic distribution, and subsequently, this subset of PCa patients was excluded from the association analyses to avoid the intra-ethnic bias.
Ku70/80 is a protein complex encoded by XRCC6 and XRCC5 genes, which is involved in starting the NHEJ process. Specifically, ku70/80 is responsible for the recognition of the DNA ends at the site where de DSB lesion takes place. 9, 34, 35 As ku70/80 is a complex formed by two different monomers, the functionality of the complex could be compromised if there are structural changes in the proteins, and it is well known that genetic polymorphisms can compromise not only the binding of a protein complex, but also the strength of the bounds between proteins and DNA.
34
XRCC6 rs2267437 appeared as a risk factor associated with clinical variables of poor prognosis for PCa in terms of tumor size, diagnostic PSA level, Gleason score and even D'Amico risk groups. The rs2267437 polymorphism has been investigated as a risk factor for cancer risk with inconsistent results. However, a recent systematic review and meta-analysis concluded that rs2267437 SNP is associated with a significant increase in risk of breast cancer, renal cell carcinoma and hepatocellular carcinoma. 36 Nonetheless, this study did not include any PCa patient and no associations with clinical variables were analyzed. The role of rs2267437-specifically the GG genotype-in cancer seems to be established in other meta-analysis. 37 Our results reinforce these previous results and postulate rs2267437 SNP as a novel genetic factor for PCa behavior.
The role of XRCC5 rs1051685 has been previously evaluated in myeloma patients. Those patients carrying the GG genotype were at lower risk of develop myeloma. 38 This result was proven among Spanish multiple myeloma patients 39 and agree with those reported in the present study in PCa patients. Although it is expectable to find a link between SNPs in XRCC5 and XRCC6, when rs2267437 and rs1051685 were analyzed together we did not observe such association, possibly due to the small amount of patients carrying the 'protective' genotype (n = 27). The minor allele frequency for rs1051685 was around 10%, and this result agrees with those reported specifically in the European population (data available at http://www.ncbi.nlm.nih.gov/projects/SNP/). With the data available, the potential role of rs1051685 polymorphism needs to be explored deeply.
We did not find previously published studies aimed to explore the association between genetic variants in PARP1 and PCa. Other SNPs in PARP1 seem to be associated with glioma 40 and gastrointestinal cancers, 41 but nothing is reported in relation to rs3219123 or PCa. In our series, we observed an association between this SNP and diagnostic PSA levels, but univariate analysis was not statistical significant. Even when rs3219123 was analyzed in combination with rs2267437, the results were less significant than those obtained with rs2267437 alone, suggesting a poor role of (PARP1) rs3219123 in the biology of PCa.
There is only one previous publication studying the role of genetic variants in MVP. It is an article aimed to explore the role of SNPs in multidrug resistant genes in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. 42 The authors did not observe any role of different SNPs in MVP-including rs3815824-in this type of patients. In that sense, MVP is an unknown gene which interest has increased as its association with Ku70/Ku80 (ref. 16 ) and its role in radiation response [43] [44] [45] in the clinical setting. We reported here for the first time that PCa patients carrying the TT genotype were at higher risk of developing worst prostate tumors in terms of diagnostic PSA level (a classical prognosis factor for this type of cancer). Moreover, when combined with (XRCC6) rs2267437, these SNPs together increased the risk of a higher D'Amico score at diagnosis. The mechanisms behind this association are unknown, but support the existing hypothesis about a potential link between MVP and NHEJ. 16 The functional consequences of the SNPs reported in the present study are difficult to address as rs2267437 and rs3815824 are intron variations which are not transduced into protein. However, introns are removed and exons are joined during a complex post-transcriptional modification of RNA named splicing, and the consequences of SNPs located in intron regions on cis regulatory elements which drive the splicing process are unknown but would influence the spliceosome. 46 Moreover, SNPs located in non-coding regions have been associated with human diseases and in any case, are needed to a better understanding of their impact on gene function and health of an individual. 47 Finally, SNPs located in intron regions are considered in in silico tools such as 'F-SNP: a collection of functional SNPs, specifically prioritized for disease association studies' (available at:
http://compbio.cs.queensu.ca/F-SNP/). This fact suggests the biological relevance of this type of genetic variations in human diseases. 48, 49 In that sense, functional studies are required to disclose the biological consequences of rs2267437 and rs3815824 in PCa.
The present study provides a number of advantages that contribute to their credibility. First, the high confidence of the genotyping system and the clinical end points considered (of total routine in daily clinical practice) minimize the possibility of inferring results because of the subjectivity of the observations. Second, the present study has been performed in a series of Spanish PCa patients who was homogeneous regarding to intraethnic variability, a factor that has been shown to be important in association studies with polymorphisms. And third, all the determinations (13 222 in total) were performed with the same methodology (OpenArray, Applied Biosystems), with the same batch of chips and by the same investigator, thus minimizing biases from technical origin. On the other hand, the present study has some weaknesses that need to be highlighted: (i) although 601 PCa patients seem sufficient to obtain statistically reliable results, it is possible that some results may be of stochastic nature (type I error), especially for those SNPs with lower minor allele frequency and taken into account that the association studies were performed in a series of 494 PCa patients; (ii) other factors associated with PCa (that is, age, familiar aggregation, toxic habits, prostate volume, testosterone level, other DNA repair genes or some kind of diets) have not been taken into account in the present study; (iii) in the present study, we did not account for multiple testing (that is, Bonferroni correction), thus limiting the strength of some statistical analyses; and (iv) functional studies to disclose the biological consequences of the SNPs are required to understand the real role of these genetic variations in PCa.
Taken together, our results suggest that genetic variants in DNA DSB repair genes and other genes close related to the NHEJ could be of relevance in PCa. An inability of cells to respond properly to, or to repair, DNA damage leads to genetic instability, which in turn may enhance the rate of cancer development or condition the aggressiveness of the tumor. Anyhow, to better understand the biological consequences of these genetic variations, other genes involved in DNA repair (such as p53, ATM, BRCA1 or BRCA2) have to be taken into account, especially when there are accumulating evidence connecting deficiencies in cellular responses to DNA DSBs with tumorigenesis. 2 
CONCLUSIONS
In summary, our study shows for the first time that (XRCC6) rs2267437 and (MVP) rs3815824 polymorphisms are associated with clinical variables of more aggressive PCa. The present results have to be considered as hypothesis generating, and additional studies with a larger separate cohort of men should be done to validate the results as well as their combined effects. Moreover, functional studies are required to understand the role of both SNPs in PCa.
